文献速递乳腺癌

男性乳腺癌的病理学特征:EORTC 10085/TBCRC/BIG/NABCG国际男性乳腺癌项目结果

Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
PubMed 文献 · Eur J Cancer · 2017-03-11

该研究对1483例男性乳腺癌进行中心病理复审,评估组织学亚型、分级、核分裂活性指数、纤维化灶及肿瘤浸润淋巴细胞密度与临床结局的相关性。中位总生存随访7.1年,组织学分级与总生存无显著相关(p=0.129),而核分裂活性指数、纤维化灶存在及低肿瘤浸润淋巴细胞密度与不良总生存相关。

要点

  • 组织学分级与男性乳腺癌总生存无显著相关(p=0.129)。
  • 核分裂活性指数、纤维化灶存在及低TIL密度与不良OS相关。
  • HER2阳性亚型TIL密度高于luminal HER2阴性亚型(p=0.015)。

核心结论

  • 在该系列中,组织学分级与临床结局无显著相关,这与女性患者中所见不同。
  • 这些结果有助于理解男性乳腺癌,并表明需进一步研究以优化男性乳腺癌患者的风险分层和治疗决策。

研究设计与样本

  • 对欧洲癌症研究与治疗组织(EORTC)国际男性乳腺癌项目第1部分收集的1483例男性乳腺癌进行中心病理复审。
  • 病理复审包括组织学亚型、分级、核分裂活性指数(MAI)、纤维化灶存在及肿瘤浸润淋巴细胞(TILs)密度。
  • 将这些特征与临床结局进行相关性分析,并评估其与免疫组化替代分子亚型的关系。

主要发现

  • 总生存(OS)的中位随访时间为7.1年。
  • 总体组织学分级与OS无显著相关(p=0.129)。
  • MAI、纤维化灶存在及低TIL密度与不良OS相关(分别为p=0.023、p=0.004和p=0.011)。
  • 乳腺癌亚型与TIL密度相关(p=0.015),观察到人表皮生长因子受体2(HER2)阳性乳腺癌的TIL密度高于luminal HER2阴性亚型。
  • 亚型与纤维化灶之间未观察到关联。

关键数值与推荐

  • 总体组织学分级与OS无显著相关(p=0.129)。
  • MAI与不良OS相关(p=0.023)。
  • 纤维化灶存在与不良OS相关(p=0.004)。
  • 低TIL密度与不良OS相关(p=0.011)。
  • 乳腺癌亚型与TIL密度相关(p=0.015),HER2阳性乳腺癌TIL密度高于luminal HER2阴性亚型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Several prognostic histological features have been established in female breast cancer (BC), but it is unknown whether these can be extrapolated to male BC patients. The aim of this study was to evaluate the prognostic value of several histological features in a large series of male BC. METHODS: Central pathology review was performed for 1483 male BCs collected through part 1 of the European Organisation for Research and Treatment of Cancer (EORTC) International Male BC Program. Pathology review included histological subtype, grade, mitotic activity index (MAI), presence of a fibrotic focus and density of tumour-infiltrating lymphocytes (TILs). These features were correlated with clinical outcome. The relationship between these features and surrogate molecular subtypes using immunohistochemistry was also assessed. RESULTS: Median follow-up for overall survival (OS) was 7.1 years. Overall histological grade was not significantly associated with OS (p = 0.129). MAI, the presence of a fibrotic focus and a low TIL density however were correlated with unfavourable OS (p = 0.023, p = 0.004 and p = 0.011, respectively). BC subtype correlated with TIL density (p = 0.015), as we observed a higher density for human epidermal growth factor receptor type 2 (HER2) positive BC compared to luminal HER2-negative subtype. No association was observed between subtype and fibrotic focus. CONCLUSIONS: Histologic grade was not significantly correlated with clinical outcome in this series, unlike what is seen in female patients. These results contribute to our understanding of male BC and indicate the importance of further research on the optimisation of risk stratification and treatment decisions for male BC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Vermeulen MA, Slaets L, Cardoso F, et al. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer. 2017. PMID: 28292559. doi:10.1016/j.ejca.2017.01.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。